For the quarter ended June 2026, Medline (MDLN Quick QuoteMDLN - Free Report) reported revenue of $7.69 billion, representing no change compared to the same period last year. EPS came in at $0.50, compared to $0 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $7.49 billion, representing a surprise of +2.67%. The company delivered an EPS surprise of +56.25%, with the consensus EPS estimate being $0.32.

While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately.

Here is how Medline performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Net sales to external customers- Supply Chain Solutions: $4.15 billion versus the four-analyst average estimate of $3.91 billion.
• Net sales to external customers- Medline Brand: $3.54 billion compared to the $3.59 billion average estimate based on four analysts.
• Adjusted EBITDA- Supply Chain Solutions: $204 million compared to the $213.9 million average estimate based on three analysts.
• Adjusted EBITDA- Medline Brand: $1.07 billion compared to the $806.16 million average estimate based on three analysts.

View all Key Company Metrics for Medline here>>>

Shares of Medline have returned -2.3% over the past month versus the Zacks S&P 500 composite's +3.5% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term.